Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) | PAR 23 041

Opportunity Information: Apply for PAR 23 041

The National Institutes of Health (NIH) is offering a discretionary grant opportunity titled "Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)," Funding Opportunity Number PAR 23 041. It supports research that uses modern genome or epigenome editing approaches to move beyond statistical genetic associations and directly test what specific genes or genetic variants do in relation to substance use disorder (SUD) relevant traits. The central aim is to generate strong functional evidence linking genes or variants to biological mechanisms that influence addiction-related phenotypes, with the longer-term goal of building a foundation for improved prevention, diagnosis, and treatment strategies. Clinical trials are not permitted under this announcement, keeping the focus on preclinical or mechanistic experimental work rather than testing interventions in human participants.

A key emphasis of the program is the use of genome editing or epigenome editing as enabling tools for functional validation and characterization. In practice, this means applicants are expected to design studies that can experimentally manipulate candidate genes or variants (for example, turning genes on or off, introducing or correcting specific variants, or modulating regulatory elements that control gene expression) and then measure impacts on SUD-relevant biological or behavioral outcomes. The initiative is geared toward clarifying neurobiological mechanisms, so projects typically align with questions about how genetic changes affect neural circuits, cellular function, gene regulation, or other mechanistic pathways that are plausibly tied to substance use, dependence, withdrawal, craving, reinforcement, or related endophenotypes.

Another major expectation is community benefit through resource sharing. The announcement states that genetic resources generated through funded projects are expected to be made broadly available to the scientific community. That generally points toward creating research-enabling tools or models (such as edited cell lines, edited animal models, variant constructs, datasets, or other validated reagents) and ensuring that other investigators can access them to accelerate progress across the field. The intent is to avoid one-off findings that cannot be followed up, and instead produce durable, reusable assets that help the broader research community interrogate addiction biology and translate discoveries into future clinical applications.

The funding mechanism is listed as a grant, with an R21/R33 structure, which commonly supports a phased approach where early-stage exploratory work can transition into an expanded phase if milestones are met. This format is often used when there is a need to prove feasibility first (such as demonstrating that an editing strategy works reliably and produces interpretable phenotypes) before scaling up into deeper characterization. The opportunity is categorized under Education and Health and is associated with CFDA number 93.279. The opportunity was created on 2022-11-01, and the original closing date is 2025-07-28. The award ceiling shown in the source data is 125,000, which indicates an upper limit as presented in the listing (applicants should still verify the detailed NIH announcement for budget rules that may depend on the specific mechanism, project duration, and NIH policy guidance). The expected awards field is not specified in the provided data.

Eligibility is broad and includes many types of domestic applicants: state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; Native American tribal organizations other than federally recognized tribal governments; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those categories); for-profit organizations other than small businesses; and small businesses. The announcement also explicitly calls out additional eligible applicant types, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-domestic (non-U.S.) entities (foreign organizations). Taken together, this makes the opportunity accessible to a wide range of research and community institutions positioned to carry out genome/epigenome editing enabled functional studies relevant to substance use disorders.

In plain terms, this opportunity is for research teams who already have strong candidate genes or variants implicated in substance use disorders (often coming from human genetic studies or other discovery pipelines) and are ready to do the hard experimental work of proving biological causality, mapping mechanisms, and creating sharable tools that help the whole field move faster.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2022-11-01.
• Applicants must submit their applications by 2025-07-28. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $125,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 23 041

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: